New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
05:34 EDTCTIC, NVSCell Therapeutics to reacquire rights to Pixuvri, Opaxio from Novartis
Cell Therapeutics (CTIC) announced that it has reached an agreement with Novartis (NVS) to reacquire rights to two anti-cancer compounds Pixuvri and Opaxio. Under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both compounds to date. Upon the effective date of termination, CTI will regain all rights that had been granted to Novartis. In exchange for Novartis' agreement to return such rights to CTI, CTI has agreed to make certain potential payments to Novartis based on sales of Opaxio and PIXUVRI and on any sublicense and certain other amounts payable to CTI.
News For CTIC;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
07:53 EDTNVSEndocyte names Alison Armour chief medical officer
Endocyte (ECYT) announced that Alison A. Armour has been appointed as chief medical officer. Prior to joining Endocyte, Dr. Armour served as vice president of oncology at Novartis (NVS) and GSK (GSK).
July 29, 2015
05:28 EDTNVSNovartis announces equity stake in Mereo BioPharma Group
Novartis announced a swap of clinical assets for equity with Mereo BioPharma Group. The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under the terms of the agreement, Novartis will have an equity stake in Mereo and will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales.
July 27, 2015
05:22 EDTCTICCTI BioPharma appoints Bruce Seeley as Chief Commercial Officer
Subscribe for More Information
July 24, 2015
10:56 EDTNVSNovartis announces FDA approval of Odomzo
Subscribe for More Information
09:02 EDTNVSLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information
07:17 EDTNVSNovartis combination therapy Tafinlar, Mekinist achieves regulatory milestones
Subscribe for More Information
July 22, 2015
07:03 EDTNVSIgnyta names Bernard Parker as Chief Commercial Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use